Skip to content
- Synergistic effect of PARP inhibitor and BRD4 inhibitor in multiple models of ovarian cancer.
- Huang Y, Liu C, You L, Li X, Chen G, Fan J.
- J Cell Mol Med. 2023 Feb 8. doi: 10.1111/jcmm.17683. Epub ahead of print.
- Germline cancer gene expression quantitative trait loci are associated with local and global tumor mutations.
- Liu Y, Gusev A, Kraft P.
- Cancer Res. 2023 Feb 6:CAN-22-2624. doi: 10.1158/0008-5472.CAN-22-2624. Epub ahead of print.
- APE2: catalytic function and synthetic lethality draw attention as a cancer therapy target.
- McMahon A, Zhao J, Yan S.
- NAR Cancer. 2023 Feb 6;5(1):zcad006. doi: 10.1093/narcan/zcad006.
- Current status and future promise of next-generation poly (ADP-Ribose) polymerase 1-selective inhibitor AZD5305.
- Zheng J, Li Z, Min W.
- Front Pharmacol. 2023 Jan 23;13:979873. doi: 10.3389/fphar.2022.979873.